Clinical Features and Diagnosis of Thrombotic Thrombocytopenic Purpura
TTP diagnosis requires ADAMTS13 activity <10% in the context of severe thrombocytopenia (usually <30 × 10⁹/L) and microangiopathic hemolytic anemia, and treatment must be initiated immediately upon clinical suspicion without waiting for ADAMTS13 results. 1
Core Clinical Features
The classic presentation includes:
- Severe thrombocytopenia (typically <30 × 10⁹/L) 1
- Microangiopathic hemolytic anemia with:
- Low hemoglobin and hematocrit
- Elevated lactate dehydrogenase (LDH)
- Schistocytes (fragmented red blood cells) on blood smear
- Low or absent haptoglobin 1
- Variable degrees of end-organ damage affecting brain, kidneys, heart, or other organs 1
Critical caveat: The historical "pentad" (thrombocytopenia, hemolytic anemia, neurologic symptoms, renal dysfunction, fever) is NOT required for diagnosis. Waiting for all five features delays treatment and increases mortality. 2 In fact, schistocytes may even be absent in some cases despite active disease. 2
Diagnostic Algorithm
Step 1: Clinical Suspicion and Risk Stratification
When you see thrombocytopenia + hemolytic anemia, immediately calculate a clinical prediction score BEFORE ADAMTS13 results return:
These scores estimate the likelihood of severe ADAMTS13 deficiency and guide whether to initiate treatment empirically.
Step 2: Laboratory Confirmation
The diagnostic gold standard is ADAMTS13 activity measurement: 2, 4
- ADAMTS13 activity <10 IU/dL (or <10% of normal) = diagnostic for TTP in appropriate clinical context 1, 2
- ADAMTS13 activity >10% = consider alternative thrombotic microangiopathy (atypical HUS, drug-induced TMA, etc.) 5
Key laboratory findings supporting TTP:
- Elevated LDH (often >1500 U/L indicates worse prognosis) 6
- Negative direct antiglobulin test (excludes immune hemolysis)
- Elevated indirect bilirubin
- Elevated creatinine (variable renal involvement)
- Elevated troponin (cardiac involvement worsens prognosis) 2
Step 3: Subtype Classification
After confirming ADAMTS13 deficiency, determine the etiology:
Immune TTP (iTTP):
- Positive anti-ADAMTS13 IgG autoantibodies or inhibitors 1
- Important pitfall: Absence of detectable antibodies during acute episodes does NOT rule out iTTP—free antibodies may be undetectable due to immune complex formation or accelerated clearance 1
- More common in adults, especially women 7
Congenital TTP (cTTP):
- Requires repeated negative antibody testing after therapy 1
- Confirmed by genetic testing showing ADAMTS13 mutations (approximately 250 causative mutations identified) 1
- Most patients have compound heterozygous mutations 1
- More likely in neonates/children but can present in adulthood 2
TTP of unknown cause (uTTP):
- ADAMTS13 <10% without detectable antibodies or genetic mutations 2
- Recently described entity requiring further research 4
Critical Management Points
Treatment MUST begin immediately when TTP is suspected clinically—do not wait for ADAMTS13 results. 2 The turnaround time for ADAMTS13 testing can be several days, and delays in treatment directly increase mortality. 2, 4
Poor prognostic indicators requiring aggressive management:
- Age >45 years 6
- Pentad symptoms present 6
- LDH >1500 U/L 6
- Consciousness impairment 2
- Cardiac involvement (troponin elevation) 2
- Acute kidney injury 2
- Stroke 2
Differential Diagnosis Considerations
TTP can be difficult to distinguish from other thrombotic microangiopathies. 2 In a retrospective study, only 6% of TMA cases were primary TTP—most were secondary to pregnancy, infection, drugs, malignancies, or transplantation. 2 This emphasizes the importance of ADAMTS13 testing to differentiate true TTP from other TMAs, as management differs substantially.
The key distinguishing feature: Severe ADAMTS13 deficiency (<10%) is specific for TTP, while other TMAs typically have normal or only moderately reduced ADAMTS13 activity. 5